Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 10/20 | 0.77 |
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.77 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | TACR3 | P29371 | 4/20 | 0.54 |
| ▸ | TACR2 | P21452 | 2/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | TACR1 | P25103 | 1/20 | 0.54 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.54 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Oxycinchophen SCHEMBL29460357 | 0.87 | DHODH (1.00) | DHODHPDE10ALMNATSHRTACR3 | |
| Oxycinchophen SCHEMBL1170683 | 0.87 | DHODH (1.00) | DHODHPDE10ALMNATSHRTACR3 | |
| Oxycinchophen SCHEMBL31654029 | 0.87 | DHODH (1.00) | DHODHPDE10ALMNATSHRTACR3 | |
| SCHEMBL13971502 | 0.84 | DHODH (0.77) | DHODHPDE10ALMNATSHRTACR3 | |
| SCHEMBL9501979 | 0.84 | DHODH (1.00) | DHODHPDE10ALMNATSHRCYP2D6 | |
| SCHEMBL13957847 | 0.84 | LMNA (0.77) | DHODHPDE10ALMNATSHRTACR3 | |
| SCHEMBL4463839 | 0.83 | PDE10A (0.77) | DHODHPDE10ALMNATSHRTACR3 | |
| SCHEMBL7692816 | 0.83 | DHODH (0.56) | DHODHPDE10ALMNATSHRTACR3 | |
| SCHEMBL13957865 | 0.80 | TACR3 (0.62) | DHODHPDE10ALMNATSHRTACR3 | |
| SCHEMBL4230222 | 0.80 | DHODH (0.70) | DHODHPDE10ALMNATSHRTACR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080280949-A1 | Oxopyridyl Quinoline Amides as Nk3 Receptor Modulators | ASTRAZENECA AB (SE) | 2008-11-13 | — | — | US | disclosed |
| CN-101287723-A | Amidoalkylpyridylquinolines as NK3 receptor modulators | ASTRAZENECA AB (SE) | 2008-10-15 | — | — | CN | disclosed |
| CN-101282964-A | Oxopyridyl quinoline amides as NK3 receptor modulators | ASTRAZENECA AB (SE) | 2008-10-08 | — | — | CN | disclosed |
| US-20080200504-A1 | non-peptide NK-3 receptor ligands; anxiety, depression, schizophrenia, obesity; 2-Phenyl-quinoline-4-carboxylic acid (1-pyridin-4-yl-propyl) amide; reacting the 2-phenyl-quinolinyl-4-carbonyl chloride with a pyridylalkylamine to form the amide | ASTRAZENECA AB (SE) | 2008-08-21 | — | — | US | disclosed |
| US-20080194622-A1 | Quinoline 3-Sulfonate Esters as Nk3 Receptor Modulators | ASTRAZENECA AB (SE) | 2008-08-14 | — | — | US | disclosed |
| EP-1915362-A1 | AMIDE ALKYL PYRIDIYL QUINOLINES AS NK3 RECEPTOR MODULATORS | AstraZeneca AB (SE) | 2008-04-30 | — | — | EP | disclosed |
| EP-1915363-A1 | OXOPYRIDYL QUINOLINE AMIDES AS NK3 RECEPTOR MODULATORS | AstraZeneca AB (SE) | 2008-04-30 | — | — | EP | disclosed |
| WO-2007018465-A1 | AMIDE ALKYL PYRIDIYL QUINOLINES AS NK3 RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2007-02-15 | — | — | WO | disclosed |
| WO-2007018469-A1 | OXOPYRIDYL QUINOLINE AMIDES AS NK3 RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2007-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280949-A1 | Oxopyridyl Quinoline Amides as Nk3 Receptor Modulators | KCNA3, KCNQ3, GPR3 | DHODH 2547/4885PDE10A 2448/4885LMNA 3842/4885 |
| US-20080200504-A1 | non-peptide NK-3 receptor ligands; anxiety, depression, schizophrenia, obesity; 2-Phenyl-quinoline-4-carboxylic acid (1-pyridin-4-yl-propyl) amide; reacting the 2-phenyl-quinolinyl-4-carbonyl chloride with a pyridylalkylamine to form the amide | NPY4R, PROKR1, NPSR1 | DHODH 4351/4885PDE10A 3503/4885LMNA 2776/4885 |
| US-20080194622-A1 | Quinoline 3-Sulfonate Esters as Nk3 Receptor Modulators | KCNQ3, KCNA3, GPR3 | DHODH 3201/4885PDE10A 1695/4885LMNA 3448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.